Table 3.

Proportion of Participants With 30-Day Rehospitalization and All-Cause Mortality by Treatment Arm and Antibacterial Subgroups

	Bezlotoxumab			Placebo
	Metronidazole	Vancomycin	Fidaxomicin	Metronidazole	Vancomycin	Fidaxomicin
30-day rehospitalizations, % (n/N)
All-cause	22.0 (n = 54/246)	22.7 (n = 61/269)	53.3 (n = 8/15)	25.6 (n = 62/242)	27.9 (n = 74/265)	30.8 (n = 4/13)
CDI-related	4.9 (n = 12/246)	5.2 (n = 14/269)	6.7 (n = 1/15)	8.3 (n = 20/242)	14.0 (n = 37/265)	7.7 (n = 1/13)
Mortality, % (n/N)
30-day	4.0 (n = 15/377)	3.2 (n = 12/380)	0.0 (n = 0/29)	4.2 (n = 16/380)	2.7 (n = 10/374)	3.7 (n = 1/27)
90-day	7.4 (n = 28/377)	6.3 (n = 24/380)	6.9 (n = 2/29)	8.4 (n = 32/380)	6.7 (n = 25/374)	7.4 (n = 2/27)

Abbreviation: CDI, Clostridioides difficile infection.